瑞普生物(300119.SZ):員工持股計劃存續期到期擬延期
格隆匯 8 月 21日丨瑞普生物(300119.SZ)公佈,基於目前證券市場的情況,為切實發揮員工持股計劃實施的目的和激勵作用,最大程度維護各持有人利益,2020年8月20日公司召開了員工持股計劃持有人會議,經出席持有人會議的持有人所持2/3以上份額同意,通過了《關於瑞普生物員工持股計劃延期的議案》,同意向公司董事會申請員工持股計劃存續期延期一年,即存續期延長至2021年8月23日。
截至公告披露日,公司員工持股計劃已累計出售股票239.5342萬股,剩餘股票數量239.5542萬股,佔目前公司總股本比例的0.59%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.